The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years

This is the first study where OMA-treated CSU patients were followed up to six years. In half of them, long-term therapy of six years is still required.

Authors

Institutions

Publication Details

Journal
Frontiers in Allergy
Published
2024-10-02
DOI
https://doi.org/10.3389/falgy.2024.1464466
Primary Topic
Urticaria and Related Conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years

Vered Schichter‐Konfino, Zehava Vadasz, Raeda Mubariki, Elias Toubi
Frontiers in Allergy
Urticaria and Related Conditions
article

The prevalence of patients suffering from chronic spontaneous urticaria, in whom omalizumab cannot be stopped even after six years

Vered Schichter‐Konfino, Zehava Vadasz, Raeda Mubariki, Elias Toubi
article en

Abstract

This is the first study where OMA-treated CSU patients were followed up to six years. In half of them, long-term therapy of six years is still required.

Frontiers in AllergyVol. 5
Hillel Yaffe Medical Center (IL), Holy Family Hospital Nazareth (IL), Bnai Zion Medical Center (IL), Rappaport Family Institute for Research in the Medical Sciences (IL)
Good health and well-being
Openalex Percentile: Top 70%
Urticaria and Related Conditions
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.